A PHASE 2A, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE MULTIPLE DOSING REGIMENS OF SUBCUTANEOUS ALXN1820 IN ADULT PATIENTS WITH SICKLE CELL DISEASE

Registry ID

ALXN1820-SCD-201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ALEXION PHARMACEUTICALS INC

Start date

2023-08-02

Last update

2022-11-02

Conditions

• SICKLE CELL DISEASE

Related clinical trials

• A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING, EFFICACY, AND SAFETY STUDY OF TEBAPIVAT IN PARTICIPANTS WITH SICKLE CELL DISEASE
• EARLY HLA MATCHED SIBLING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE: A SICKLE TRANSPLANT ALLIANCE FOR RESEARCH (STAR) TRIAL
• A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MITAPIVAT IN SUBJECTS WITH SICKLE CELL DISEASE
• THROMBOPROPHYLAXIS IN SICKLE CELL DISEASE WITH CENTRAL VENOUS CATHETERS (THIS): A PILOT STUDY
• "A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A SINGLE DOSE OF AUTOLOGOUS CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS GENE-EDITED CD34+ HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS (EDIT-301) IN SUBJECTS WITH SEVERE SICKLE CELL DISEASE"
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA/ HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PATIENTS WITH VASO-OCCLUSIVE CRISES (STAND)

View on source registry